Precision Sarcoma Research
- Functional and Structural Genomics
- NCT
- Junior Research Group
Dr. Priya Chudasama
Group leader
We investigate molecular and clinical profiles of sarcomas through structural and functional genomics approaches to better understand sarcomagenesis and nominate biomarkers and precision therapeutics for clinical evaluation in sarcoma patients.
Our Research
Sarcomas are mainly divided into two types, bone sarcoma and soft-tissue sarcoma. Sarcomas display remarkable genetic and histologic diversity, as reflected by more than 150 subtypes according to the World Health Organization Classification, which in turn poses significant diagnostic and therapeutic difficulties. “Actionable” lesions that allow prediction of response to conventional or targeted anti-cancer drugs and/or represent direct targets for therapeutic intervention are lacking in the majority of cases due to incomplete understanding of the events that drive sarcoma development.
The Precision Sarcoma Research group funded by the Emmy Noether Program of the German Research Foundation (DFG) has been established to improve the understanding of sarcomagenesis and identify targets for biological stratification and molecular mechanism-guided therapeutic intervention.
We have established an integrated pipeline connecting foundational science to translation, beginning with clinical discovery and moving through robust experimental validation to deliver clinically relevant therapeutic targets and biomarkers for evaluation in sarcoma patients. Our approach is to map sarcoma subtype-specific disease programs in order to understand how they can be targeted most efficiently.
Our team brings expertise across a diverse set of topics, matched to the heterogeneity of sarcoma biology: structural genomics, genomic instability and DNA damage biology; immune cell types and interactions within the tumor microenvironment; energy metabolism and metabolomics; and more broadly applicable analytical approaches including machine learning and multi-omics factor analysis. This breadth allows us to investigate the biology of a diverse set of sarcoma subtypes across the full spectrum of genetic aberrations, from fusion-driven sarcomas to those displaying high levels of genomic instability, from soft-tissue to bone sarcomas, and from common to ultra-rare entities.
In a project-specific manner, we apply the latest technology platforms, including long-read sequencing, single-nucleus sequencing (scATAC, scRNA-seq, scWGS) and spatial transcriptomics, to gain deeper insight into the biology of these tumors. Mechanistic investigation of selected aberrations is enabled by our expanding panel of model systems and a comprehensive functional genomics toolkit (e.g. CRISPR/Cas9 libraries). Strongly grounded biology and robust validation ensure that the sparse translational opportunities in these rare cancers are pursued with the best possible odds of success.
Our goal is evidence-based path forward and improved clinical care for each sarcoma patient.